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ABSTRACT
The acute-phase protein haptoglobin (Hpt) binds apolipopro-
tein A-I (ApoA-I) and impairs its action on lecithin-cholesterol
acyltransferase, an enzyme that plays a key role in reverse
cholesterol transport. We have previously shown that an ApoA-I
mimetic peptide, P2a, displaces Hpt from ApoA-I, restoring the
enzyme activity in vitro. The aim of this study was to evaluate
whether P2a displaces Hpt from ApoA-I in vivo and whether
this event leads to anti-inflammatory activity. Mice received
subplantar injections of carrageenan. Paw volume was mea-
sured before the injection and 2, 4, 6, 24, 48, 72, and 96 h
thereafter. At the same time points, concentrations of HDL
cholesterol (C) and cholesterol esters (CEs) were measured by
high-performance liquid chromatography, and Hpt and ApoA-I
plasma levels were evaluated by enzyme-linked immunosor-
bent assay. Western blotting analysis for nitric-oxide synthase
and cyclooxygenase (COX) isoforms was also performed on
paw homogenates. CEs significantly decreased in carrageenan-
treated mice during edema development and negatively corre-
lated with the Hpt/ApoA-I ratio. P2a administration significantly
restored the CE/C ratio. In addition, P2a displayed an anti-
inflammatory effect on the late phase of edema with a signifi-
cant reduction in COX2 expression coupled to an inhibition of
prostaglandin E2 synthesis, implying that, in the presence of
P2a, CE/C ratio rescue and edema inhibition were strictly re-
lated. In conclusion, the P2a effect is due to its binding to Hpt
with consequent displacement of ApoA-I that exerts anti-
inflammatory activity. Therefore, it is feasible to design drugs
that, by enhancing the physiological endogenous protective
role of ApoA-I, may be useful in inflammation-based
diseases.
Introduction
Homeostasis of cholesterol (C) is essential for cell function
and survival because cholesterol is toxic when it accumulates
in the plasma membrane or within the cells. In atherogene-
sis, a critical role is played by the process known as reverse
cholesterol transport (RCT), through which the accumulated
cholesterol is transported from the vessel wall to the liver for
excretion. This process includes acceptors such as high-den-
sity lipoproteins (HDLs), apolipoprotein A-I (ApoA-I), apoli-
poprotein E, lecithin-cholesterol acyltransferase (LCAT) (EC
2.3.1.43), and several other enzymes (Rader, 2006; Rader et
al., 2009). Evidence has suggested a protective role for HDLs
in atherosclerosis based on their ability to promote RCT
(Rader, 2006). At present, it is still unclear whether part of
the “protective” effect of HDLs is due to functions beyond
RCT and whether these functions could be enhanced or re-
duced after the interaction with circulating proteins. Indeed,
it is known that HDLs undergo dramatic modification in
structure and composition as a result of the concerted actions
of the acute-phase response protein and inflammation
(Khovidhunkit et al., 2004; Esteve et al., 2005). In these
conditions, HDL particles progressively lose normal biologi-
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cal activities and acquire altered properties (Kontush and
Chapman, 2006). For example, the replacement of ApoA-I
with serum amyloid A, occurring in small, dense HDLs upon
induction of the acute phase of inflammation (Parks and
Rudel, 1985; Coetzee et al., 1986), has been reported to have
proatherogenic effects (Cabana et al., 1996; Lewis et al.,
2004; O’Brien et al., 2005).
The critical role of inflammation at all stages of atheroscle-
rosis is now recognized, including triggers, mediators, and
end-effectors (Kontush and Chapman, 2006; Libby, 2007). In
several studies, we have shown that the acute-phase protein
haptoglobin (Hpt) binds the HDL protein components ApoA-I
and apolipoprotein E, impairing their key functions in RCT
(Porta et al., 1999; Spagnuolo et al., 2005; Salvatore et al.,
2007, 2009; Cigliano et al., 2009). Haptoglobin is a polymor-
phic glycoprotein that exhibits phenotype prevalence in car-
diovascular diseases (Delanghe et al., 1997). Its circulating
levels are enhanced during the acute phase of inflammation
to capture and transport free hemoglobin to the liver (Lan-
glois and Delanghe, 1996). ApoA-I, the major protein compo-
nent of HDL, plays a key role in reverse cholesterol trans-
port. This protein stimulates the efflux of cellular cholesterol
and activates the enzyme LCAT, which in turn converts the
free cholesterol into cholesteryl esters (CEs), addressing
them to HDLs for transport into the circulation (Rader and
Daugherty, 2008). The binding of Hpt to ApoA-I is associated
with inhibition of LCAT activity and reduction of ApoA-I-
mediated delivery of cholesterol to hepatocytes leading to 1)
poor cholesterol removal from peripheral cells and 2) a low
level of HDL cholesterol in the circulation (Spagnuolo et al.,
2005; Salvatore et al., 2007; Cigliano et al., 2009). Moreover,
several studies have confirmed that high levels of Hpt are
associated with increased risk of developing cardiovascular
events or myocardial infarction (Braeckman et al., 1999; De
Bacquer et al., 2001; Matuszek et al., 2003). We have previ-
ously shown that an ApoA-I mimetic peptide with an amino
acid sequence overlapping the stimulatory site for LCAT (P2a:
acetyl-LSPLGEEMRDRARAHVDALRTHLA-amide) efficiently
displaced Hpt from ApoA-I. In addition, in an in vitro setting,
P2a was able to rescue the stimulatory function of ApoA-I in the
presence of high Hpt levels, whereas, when incubated without
Hpt, it did not affect LCAT cholesterol esterification (Spagnuolo
et al., 2005). Because the anti-inflammatory activity of HDLs
and ApoA-I has been well documented (Kontush and Chapman,
2006; Rader, 2006; Gomaraschi et al., 2008; Sherman et al.,
2010), we hypothesized that the ApoA-I mimetic peptide P2a
could also be effective in vivo in displacing Hpt from ApoA-I,
leaving this apolipoprotein available for anti-inflammatory ac-
tivity. In this study, we show that the peptide P2a rescues
LCAT-dependent cholesterol esterification in vivo causing, in
addition, an anti-inflammatory effect.
Materials and Methods
Drugs and Reagents. Sheep anti-ApoA-I and sheep anti-Hpt
polyclonal antibody were purchased from Serotec (Oxford, UK).
[1,2-3H]Cholesterol (45 Ci/mmol) was obtained from PerkinElmer
Life and Analytical Sciences (Waltham, MA). SIL G plates for thin-
layer chromatography (thickness 0.25 mm) were obtained from Ma-
cherey-Nagel (Du¨ren, Germany). Chemicals of the highest purity,
bovine serum albumin (BSA), cholesterol, cholesteryl linoleate, don-
key anti-sheep IgG horseradish-linked, o-phenylenediamine, dex-
tran sulfate (Dextralip 50), carrageenan, molecular mass markers,
and SUPELCOSIL LC-18 (5-m particle size, 250  4.6 mm i.d.)
were obtained from Sigma-Aldrich (St. Louis, MO). Polystyrene 96-
well plates were purchased from Nunc (Roskilde, Denmark). Brad-
ford reagent was obtained from Bio-Rad Laboratories (Milan, Italy).
The antibodies against COX2 and iNOS were from Transduction
Laboratories (Lexington, KY). [3H]PGE2 was from Perkin-Elmer
(Milan, Italy). All other reagents and compounds used were obtained
from Sigma-Aldrich (Milan, Italy).
Peptide Synthesis. The peptide P2a (ApoA-I sequence from L141
to A164; acetyl-LSPLGEEMRDRARAHVDALRTHLA-amide) and
the scramble peptide control (P2as: acetyl-RLSARLTLHEGPVAL-
DEMRADRHA-amide) were solid phase-synthesized using PAL-
PEG-PS resin (0.16 mmol/g) (Applied Biosystems, Foster City, CA)
by standard N-(9-fluorenyl) methoxycarbonyl chemistry. Amino acid
coupling was performed using a 10 M excess of N-(9-fluorenyl) me-
thoxycarbonyl-amino acid, 9.9 Eq of 2-(1H-benzotriazole-1-yl)-
1,1,3,3-tetramethyluronium hexafluorophosphate-1-hydroxybenzo-
triazole, and 20 Eq of N,N-diisopropylethylamine. A solution of 30%
piperidine in N,N-dimethylformamide was used in the deprotection
step (two 5-min washes). The coupling reaction was performed for 60
min followed by a 10-min acetylation step with acetic anhydride (2
M)-N,N-diisopropylethylamine (0.55 M)-1-hydroxybenzotriazole (0.06
M) in N-methylpyrrolidone. Cleavage from the resin was achieved by
treatment with trifluoroacetic acid, triisopropyl silane, ethanedithiol,
and water (94:1:2.5:2.5, v/v/v/v) at room temperature for 3 h. Peptide
analysis and purification were performed by reverse-phase-HPLC on a
C12 Proteo column (Phenomenex, Torrance, CA) using a gradient of
CH3CN (0.1% trifluoroacetic acid) in water (0.1% trifluoroacetic acid)
going from 20 to 50% in 30 min. Peptide identities were assessed by
electrospray ionization mass spectrometry on a Thermo Finnigan MSQ
liquid chromatograph-mass spectrometer (P2a: molecular mass exper-
imental 2755.5 Da, molecular mass calculated 2756.1; P2as: molecular
mass experimental 2755.8 Da, molecular mass calculated 2756.1 Da).
Mouse Paw Edema.Male Swiss mice (CD-1; Harlan, Correzzana
Italy) weighing 28 to 30 g were used for in vivo experiments. The
experimental procedures were performed in accordance with the
Guide for the Care and Use of Laboratory Animals (National Insti-
tutes of Health, publication 86-23, revised 1985) as well as the
specific guidelines of the Italian (N.116/1992) and European Council
law (N.86/609/CEE). Animals were divided into groups (n  6/group)
and lightly anesthetized with isoflurane. Each group of animals
received subplantar injections of 50 l of carrageenan 1% (w/v) or 50
l of vehicle (saline) in the left hind paw. Paw volume was measured
by using a hydroplethysmometer specially modified for small vol-
umes (Ugo Basile, Comerio, Italy) immediately before the subplantar
injection and 2, 4, 6, 24, 48, 72, and 96 h thereafter. The same
operator always performed the double-blind assessment of paw vol-
ume. The increase in paw volume was calculated as the difference
between the paw volume measured at each time point and the basal
paw edema. Each group of animals received intraperitoneal (100 l)
administration of P2a peptide (0.3, 0.6, or 1 mg/kg), P2as peptide (1
mg/kg), or vehicle (saline). All peptides were administrated immedi-
ately before the injection of carrageenan and 24 h thereafter.
ApoA-I and Hpt Immunoassay. The concentration of ApoA-I
and Hpt was determined by ELISA using mouse antigens as stan-
dards for calibration, isolated as reported previously (Spagnuolo et
al., 2003) and exhibiting more than 98% purity by electrophoresis
and densitometry analysis. Aliquots of plasma (50 l from 1:1000,
1:10,000, 1:20,000, 1:45,000, 1:60,000, and 1:100,000 dilutions) were
diluted in coating buffer (7.3 mM Na2CO3, 17 mM NaHCO3, and 1.5
mM NaN3, pH 9.6), loaded into the wells of a microtiter plate, and
processed essentially according to a published procedure (Cigliano et
al., 2005). In particular, sheep IgG (anti-ApoA-I or anti-Hpt, respec-
tively) was used as the primary antibody and donkey anti-sheep IgG
horseradish-linked IgG as the secondary antibody for color develop-
ment. Measurements were performed using a calibration curve, ob-
tained by determining the immunoreactivity of 1, 0.5, 0.25, 0.125,
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0.065, 0.033, and 0.016 ng of standard Hpt protein and 0.4, 0.24,
0.16, 0.08, 0.04, and 0.016 ng of standard ApoA-I protein.
LCAT Activity Assay. Plasma samples from treated and control
animals were treated with 50 mM MnCl2 and 0.1% dextran sulfate
(50 kDa) according to a published procedure to remove very-low-
density lipoprotein and low-density lipoprotein (Burstein et al.,
1970). The LCAT activity in vitro was measured using proteolipo-
somes (ApoA-I/lecithin/cholesterol molar ratio of 1.5:200:18) as sub-
strate as reported previously (Spagnuolo et al., 2005; Cigliano et al.,
2009). The enzyme activity was expressed as enzyme units (nano-
moles of cholesterol esterified per hour per milliliter of plasma).
Titration of Cholesterol and Cholesteryl Esters in HDLs.
The ratio of CE with unesterified C in HDLs was assumed to reflect
the LCAT activity in the plasma (Cigliano et al., 2005). Plasma
samples of treated or control animals were treated with 50 mM
MnCl2 and 0.1% dextran sulfate (50 kDa) according to a published
procedure to remove very-low-density lipoprotein and low-density
lipoprotein (Burstein et al., 1970). After this treatment, two 25-l
aliquots were used for measuring the amounts of unesterified and
total C. One aliquot was incubated (1 h; 75°C) with 0.25 ml of
ethanol, whereas the other one was incubated with 0.25 ml of ethanol
containing 5 M KOH. After incubation, both mixtures were supple-
mented with 0.15 ml of 1% NaCl and, after addition of 2 ml of ice-cold
hexane, were vigorously shaken for 2 min. The hexane extract was
added, and the lower phase was likewise extracted two more times.
The three extracts were pooled and dried under a nitrogen stream.
The residue was dissolved in 0.2 ml of acetonitrile-isopropanol (57:
43, v/v), and 20 l were processed by reverse-phase HPLC. Chroma-
tography was performed on a C18 column at 40°C with 1 ml/min flow
rate, according to a published procedure (Cigliano et al., 2005). The
amounts of unesterified and total cholesterol (HDL-C) were mea-
sured in samples processed without and with KOH, respectively, and
used to calculate the amount of CEs as “total minus unesterified
cholesterol.” Calibration curves (r2  0.9997), obtained by injecting
different amounts (n  12) of standard C, were used for quantitative
analysis.
Western Blot Analysis. Paws from different groups of mice were
harvested 24 and 48 h after carrageenan or vehicle injection and
homogenized in modified radioimmunoprecipitation assay buffer (50
mM Tris-HCl, pH 7.4, 1% Triton X-100, 0.25% sodium deoxycholate,
150 mM NaCl, 1 mM EDTA, 1 mM phenylmethanesulfonyl fluoride,
10 g/ml aprotinin, 20 mM leupeptin, and 50 mM NaF) using a
Polytron homogenizer (two cycles of 10 s at maximum speed) on ice.
After centrifugation at 12,000 rpm for 15 min, the protein concen-
tration was determined by Bradford assay using BSA as standard
(Bio-Rad Laboratories), and 40 g of the denatured proteins were
separated on 10% SDS-polyacrylamide gel electrophoresis and trans-
ferred to a polyvinylidene difluoride membrane. Membranes were
blocked in phosphate-buffered saline-Tween 20 (0.1%, v/v) contain-
ing 5% nonfat dry milk and 0.1% BSA for 1 h at room temperature
and then were incubated with anti-COX2 (1:1000) anti-iNOS (1:
1000) overnight at 4°C. The filters were washed with phosphate-
buffered saline-Tween 20 (0.1%, v/v) extensively for 30 min before
incubation for 2 h at 4°C with the secondary antibody (1:5000)
conjugated with horseradish peroxidase anti-mouse IgG. The mem-
branes were then washed, and immunoreactive bands were visual-
ized using ECL (GE Healthcare, Chalfont St. Giles, Buckingham-
shire, UK).
PGE2 Exudate Levels. Mice from different groups were eutha-
nized 24 and 48 h after carrageenan or vehicle injection. Paws were
cut and centrifuged at 4000 rpm for 30 min. Exudates (supernatants)
were collected with 100 l of saline and used for PGE2 quantification.
To determine PGE2 levels, proteins were removed from the exudates
with 30% ZnSO4 for 15 min (Thomsen et al., 1990). PGE2 was
determined in deproteinized exudates by radioimmunoassay accord-
ing to the manufacturer’s instructions.
Statistical Analysis. Result are expressed as mean  S.E.M. or
as mean  S.D. Statistical analysis was performed by analysis of
variance followed by the Bonferroni test for multiple comparisons or
t test analysis where appropriate, using GraphPad Prism software
(GraphPad Software Inc., San Diego, CA). Differences were consid-
ered statistically significant when p  0.05. Each sample was pro-
cessed at least in triplicate.
Results
Cholesterol Esterification Is Reduced in Mouse
Edema. The HDL fraction was isolated from plasma of car-
rageenan-treated mice after 2,4, 6, 24, 48, 72, 96, and 144 h.
The molar concentration of C and CEs was measured, and
the molar ratio CE/C was calculated as an index of LCAT
activity ex vivo (Subbaiah et al., 1997; Furbee et al., 2001).
In the early phase of carrageenan-induced inflammation
(0–6 h), no differences were found in the CE/C ratio com-
pared with that for the vehicle (data not shown). In the late
phase of inflammation (24–48 h), the values of the CE/C
ratio were found to be significantly decreased in carrageen-
an-treated mice (21.5  1 at time 0 versus 12  0.6 at 24 h,
p  0. 01; 21.5  1 at time 0 versus 10.5  0.9 at 48 h, p 
0. 01) (Fig. 1), whereas no change was detected in controls.
LCAT activity in vitro was not significantly modified by
carrageenan injection at the time points tested (data not
shown). The levels of apolipoprotein A-I, the protein that
stimulates the enzyme LCAT, were found to be unchanged in
inflamed mice (Fig. 2). These results suggest that, in carra-
geenan-treated mice, a plasma factor influences the choles-
terol esterification, and this effect is not assessable in vitro.
Correlation between the Ratio of Hpt/ApoA-I and
CE/C. Haptoglobin binds ApoA-I, the main stimulator of
LCAT, thus inhibiting the enzyme activity and the efficiency
of the reverse cholesterol transport (Spagnuolo et al., 2005;
Salvatore et al., 2007; Cigliano et al., 2009). The plasma level
of Hpt was measured in carrageenan-treated mice (Fig. 2).
The change in Hpt level after carrageenan injection showed a
biphasic trend: an early increase peaking 2 h after the car-
rageenan injection (29.1  1.5 M in inflamed mice versus
14.1  0.5 M in controls; p  0.01) and a second late
response peaking 48 h after (66.6  4 M in inflamed mice
versus 13.8  2.8 M in controls; p  0.01), returning to
the physiological values at 144 h (14.2  3 M in inflamed
mice versus 13.4  2.1 M in controls). The Hpt/ApoA-I ratio
Fig. 1. C and CE ratio in HDLs isolated from mice plasma. Groups of
three animals were sacrificed at 2, 4, 6, 24, 48, 72, 96, and 144 h after
injection of carrageenan. The control group received vehicle only. Blood
was collected, and the HDL fraction was isolated from plasma of carra-
geenan-treated mice and analyzed for C and CE content by HPLC. The
molar concentrations of C and CE in HDLs were determined, and the
molar ratio CE/C was calculated. The samples were analyzed in tripli-
cate, and the data are expressed as means  S.D.
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was found to be negatively correlated with the CE/C ratio
(p  0.01; r  0.94) (Fig. 3). These data fit well with an
inhibitory role of Hpt in the ApoA-I-dependent activity of
cholesterol esterification on HDLs.
P2a Peptide Inhibits Mouse Paw Edema in a Dose-
Dependent Manner. In the early phase of carrageenan-
induced paw edema (0–6 h), no differences were found
among groups treated with P2a at all doses tested compared
with the vehicle group (Fig. 4). In the late phase of edema
(24–96 h), injection of P2a caused a significant and dose-
dependent inhibition of edema (Fig. 4). The specificity of the
P2a effect was confirmed by the finding that the P2as did not
affect edema development in both phases (Fig. 4).
P2a Peptide Restores Cholesterol Esterification. It is
known that the binding of Hpt to ApoA-I is associated with
reduced LCAT activity. We previously found that, in vitro,
the peptide P2a, homologous to the ApoA-I sequence from
Leu141 to Ala164, displaces Hpt from ApoA-I, restoring the
activity of LCAT (Spagnuolo et al., 2005). To evaluate
whether the P2a peptide displaces Hpt in vivo, different
doses of P2a (0.3, 0.6, or 1 mg/kg i.p.) or of P2as were injected
in mice. When mice were treated with 0.6 or 1 mg/kg P2a, the
CE/C ratio was found to be significantly restored (Fig. 5A).
No effect of P2a on HDL-C was found (Fig. 5B). This result
shows that P2a, administered intraperitoneally, efficiently
engages Hpt, thus restoring ApoA-I function also in vivo.
P2a Peptide Reduces COX2 Expression and PGE2
Generation. P2a exerted its anti-inflammatory action in the
second phase of carrageenan-induced paw edema. To identify
the molecular mechanisms responsible for this anti-inflam-
matory effect, the expressions of inducible isoforms of nitric-
oxide synthase and COX, i.e., iNOS and COX2, were evalu-
ated at 24 and 48 h after carrageenan administration. As
shown in Fig. 6, Western blot analysis did not reveal any
significant alteration in COX2 expression at 24 h from edema
induction in all three groups of mice treated with P2a. In
contrast, 48 h after carrageenan injection, P2a (1 mg/kg)
significantly reduced COX2 expression (Fig. 6). The COX2
involvement was also confirmed by the significant reduction
of PGE2 levels in paw exudates obtained from mice treated
with P2a (Fig. 7). P2a administration did not affect iNOS and
eNOS expression at any time point (supplemental figure).
Discussion
It is known that the binding of Hpt to ApoA-I is associated
with reduced LCAT activity in vitro (Spagnuolo et al., 2005).
This binding, by decreasing the amount of free ApoA-I avail-
able for LCAT stimulation, impairs cholesterol esterification
(Spagnuolo et al., 2005; Salvatore et al., 2007, 2009; Cigliano
et al., 2009). The peptide P2a, which presents the ApoA-I
amino acidic sequence overlapping the domain required for
LCAT stimulation, displaces Hpt from ApoA-I and rescues
the enzyme activity in vitro (Spagnuolo et al., 2005). How-
ever, it has still not been determined whether this mecha-
nism is relevant in vivo. To address this issue, we tested
whether P2a could exert similar activity in vivo. By monitor-
ing the plasma CE/C ratio and Hpt levels during edema
development, we found an inverse correlation between CE/C
Fig. 2. Titration of Hpt in plasma from mice treated with carrageenan.
Groups of three mice were sacrificed at 2, 4, 6, 24, 48, 72, 96, and 144 h
after carrageenan injection. The control values are reported at time 0 in
the graph. Blood was collected, and plasma from each animal was pre-
pared. Samples were analyzed by ELISA for measuring the concentration
of Hpt (F) and ApoA-I (). The data are expressed as means  S.D.; n 
3 separate experiments.
Fig. 3. Correlation between Hpt/ApoA-I ratio and CE/C ratio. Plasma was
obtained from carrageenan-treated mice and control mice at different
time points. The plasma levels of Hpt and ApoA-I were measured by
ELISA, and the molar concentrations of C and CE in the HDLs were
analyzed by HPLC. Hpt/ApoA-I and CE/C ratios were calculated in trip-
licate. The Hpt/ApoA-I averages are plotted versus the homologous CE/C
averages.
Fig. 4. Effect of P2a peptide on carrageenan-induced paw edema. P2a
(0.3, 0.6, or 1 mg/kg), P2as (1 mg/kg), or vehicle was administered intra-
peritoneally immediately before the subplantar injection of carrageenan
(50 l) and 24 h thereafter. Data are expressed as means  S.E.M.; n 
6 for each group of treatment. , p  0.01; , p  0.05 versus vehicle.
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and Hpt/ApoA-I ratios. The inflammatory response induced
by carrageenan in mice is coupled with a significant increase
in Hpt levels (Salvatore et al., 2007). Therefore, in this in vivo
experimental model, Hpt acts as a competitive inhibitor of
ApoA-I for LCAT activity, causing a reduction in cholesteryl
ester production and confirming the physiopathological rele-
vance of this mechanism in inflammation. In the late phase
of mouse paw edema, P2a displayed a clear anti-inflamma-
tory effect. This effect did not involve changes in ApoA-I
levels or LCAT activity, as confirmed by the finding that
these two latter parameters were not modified in plasma
harvested by mice treated with carrageenan. Thus, the anti-
inflammatory activity of P2a should rely on different mech-
anism(s). We found that Hpt levels were elevated approxi-
mately 6-fold in the late phase of this inflammatory model.
Thus, we hypothesize that Hpt, by binding ApoA-I, impairs
LCAT function. In other words, as summarized for clarity in
Fig. 8, the effect of P2a relies on the boosting of an endoge-
nous mechanism, e.g., Hpt capture, rather than on a direct
anti-inflammatory action. This hypothesis is sustained by
the finding that systemic administration of P2a dose depend-
ently increased the CE/C ratio, rescuing it to almost physio-
logical levels at the higher dose tested (1 mg/kg). The speci-
ficity of the P2a effect was confirmed by the experiments
performed using a scrambled peptide, for which the mis-
matching of amino acid positions led to a lack of efficacy. This
effect of P2a on LCAT activity was paralleled by an anti-
inflammatory effect on the late phase of carrageenan-induced
paw edema (24–96 h). It is well know that in this mouse
model of edema COX2-derived eicosanoids and/or iNOS- or
eNOS-derived nitric oxide is involved at different time points
(Posadas et al., 2004). P2a administration did not modulate
eNOS expression. These findings correlate well with the lack
of activity of P2a in the early phase of the edema. In the late
phase, in which P2a significantly modifies the cholesterol
biochemical pathway, there was also a reduction in COX2
expression as well as of PGE2 levels. This finding implies
Fig. 5. A, effect of P2a on Hpt inhibition in cholesterol esterification.
Blood was collected by intracardiac puncture from mice treated with P2a
(0.3, 0.6, or 1 mg/kg i.p.) or P2as (1 mg/kg i.p.) 24 or 48 h after carra-
geenan injection. The HDL fraction was isolated from each plasma sam-
ple and analyzed for C and CE content by HPLC. Data are expressed as
CE/C ratio. It is notable that the increase in the CE/C ratio was strictly
related to the anti-inflammatory effect of P2a as described in Fig. 8C. The
samples were analyzed in triplicate, and the data are expressed as
means S.D. For each group of treatment n 6. , p 0.001; , p 0.01
versus treated mice 24 or 48 h after carrageenan injection. B, effect of P2a
on HDL-C. The molar concentrations of C and CE in HDLs were deter-
mined as reported for A, and the total C was calculated as C  CE. The
samples were analyzed in triplicate and the data are expressed as
means  S.D.
Fig. 6. Effect of P2a administration on COX2 expression in inflamed
paws. Twenty-four and 48 h from carrageenan injection, mice paws
harvested from different treatment groups were homogenized and West-
ern blot analysis for COX2 was performed. A, representative Western blot
for COX2. S, sham; V, vehicle, P2as, P2a scramble peptide; P2a 0.6, 0.6
mg/kg P2a; P2a 1, 1 mg/kg Pa2. B, Western blot densitometric analysis
for COX2 (n  3 experiments). Data are expressed as means  S.E.M. ,
p 0.05 versus sham; , p0.01 versus sham; o, p 0.05 versus vehicle;
oo, p  0.01 versus vehicle.
Fig. 7. Effect of P2a on PGE2 levels in inflamed paws. Twenty-four and
48 h after carrageenan injection, mouse paws harvested from different
groups of treatment were centrifuged, and exudates were collected and
used for PGE2 determination. Data are expressed as means  S.E.M. For
each treatment group n  4. , p  0.01; , p  0.001 versus sham; o,
p  0.05; oo, p  0.01 versus vehicle.
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that the two phenomena observed in presence of P2a, i.e.,
CE/C ratio rescue and edema inhibition, are related.
Our data clearly imply that P2a, by virtue of its ability to
bind Hpt, makes available more ApoA-I that acts as an en-
dogenous anti-inflammatory signal. Indeed, the P2a anti-
inflammatory effect is evident at the same time point at
which recovery of the CE/C ratio occurs, i.e., 48 h after
carrageenan injection. This hypothesis is further supported
by the fact that P2a significantly inhibits exclusively the
second phase of the edema at which the Hpt level reaches its
maximum.
In conclusion, we have demonstrated that P2a, an ApoA-
I-derived peptide with an amino acid sequence overlapping
the stimulatory site for LCAT has an anti-inflammatory ef-
fect in vivo. Discoveries in the past decade have shed light on
the complex metabolic and antiatherosclerotic pathways of
HDLs. These insights have fueled the development of HDL-
targeted drugs. In particular, many efforts were devoted to
the design of ApoA-I mimetic peptides mimicking the func-
tionality of ApoA-I (Kruger et al., 2005; Navab et al., 2005;
Buga et al., 2006; Peterson et al., 2007; Degoma and Rader,
2011). Our study suggests that it is feasible to design
drugs that can enhance the physiological endogenous pro-
tective role of ApoA-I, which may have an application
in inflammation-based cardiovascular diseases such as
atherosclerosis.
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